+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection



Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection



Annals of Internal Medicine 119(8): 786-793



To assess safety, pharmacokinetics, and in-vivo virologic activity of five different combination regimens of zidovudine and didanosine compared with zidovudine alone in patients with human immunodeficiency virus type 1 (HIV-1) infection. Open-label, partially randomized, dose-ranging study. University-affiliated, medical center clinics. A total of 69 patients with HIV-1 infection, CD4+ cell counts fewer than 400 cells/mm3, and fewer than 121 days of previous zidovudine treatment. Fifty-five patients received combination therapy with zidovudine and didanosine, and 14 received zidovudine therapy alone (600 mg/d). Daily dosages in milligrams of zidovudine and didanosine, respectively, in the five combination groups were 150 and 90 mg, 300 and 334 mg, 600 and 334 mg, 300 and 500 mg, and 600 and 500 mg. CD4+ cell counts, HIV-1 RNA titers in plasma, and toxic effects. The combination regimens were associated with higher and more sustained increases in CD4+ cells than zidovudine alone, even after adjustment for initial CD4+ counts and previous zidovudine therapy (P < 0.001). The median increase in CD4+ cell counts was 166 cells/mm3 with combination therapy and 77 cells/mm3 with zidovudine alone (P = 0.001) and did not differ statistically among the five combination regimens. Human immunodeficiency virus type 1 RNA titers in plasma decreased in 15 (83%) of 18 combination-therapy recipients compared with 2 of 7 zidovudine-alone recipients (P = 0.017). No pharmacokinetic interactions were seen between zidovudine and didanosine. Toxicity rates were low among all treatment groups. A greater decrease in hemoglobin levels was seen with the regimen using zidovudine alone (-8 g/L) compared with combination regimens using the same zidovudine dose (-1.5 g/L, P = 0.03). Combination therapy with zidovudine and didanosine produced larger and more sustained increases in CD4+ cell counts, more frequent decreases in plasma HIV-1 RNA titers, and more stable hematologic status than zidovudine therapy alone. The effects of this combination on the progression of HIV disease merit further study, to provide information about clinical outcome, because this was a relatively small study based on surrogate markers of HIV-1 infection.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 045567449

Download citation: RISBibTeXText

PMID: 8379600

DOI: 10.7326/0003-4819-119-8-199310150-00003


Related references

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 173(6): 1354-1366, 1996

Nevirapine, zidovudine, and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Annals of Internal Medicine 124(12): 1019-1030, 1996

The impact of zidovudine compared with didanosine on health status and functioning in persons with advanced HIV infection and a varying duration of prior zidovudine therapy. AIDS Clinical Trials Group 116/117 Study Group. Antiviral Therapy 1(1): 21-32, 1996

Zidovudine compared with didanosine in patients with advanced HIV type 1 infection and little or no previous experience with zidovudine. AIDS Clinical Trials Group. Archives of Internal Medicine 155(9): 961-974, 1995

A Comparative Study of a Combination of Zidovudine, Didanosine and Double Blinded Nevirapine Versus a Combination of Zidovudine and Didanosine. AMERICAN SOCIETY FOR MICROBIOLOGY [Author] Human retroviruses and related infections : 125, 1995

Combination zidovudine and didanosine therapy for patients remaining persistently hiv p24 antigen positive despite zidovudine monotherapy. Viii International Conference on Aids And The Iii Std World Congress Viii International Conference on Aids And The Iii Std World Congress; Harvard-Amsterdam Conference, Amsterdam, Netherlands, July 19-24, Pagination Varies Viii International Conference on Aids And The Iii Std World Congress: Amsterdam, Netherlands Paper : b183, 1992

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

Quality of life outcomes of combination zidovudine- didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients. Aids 14(16): 2567-2574, 2000

Retrospective study of zidovudine or didanosine monotherapy or zalcitabine plus zidovudine combination therapy in patients with early AIDS. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD [Author] Tenth International Conference on AIDS and the International Conference on STD, Vol 1; The global challenge of AIDS: Together for the future : 1) 209, 1994

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: Effect of switching to didanosine or zidovudine plus didanosine therapy. AIDS Research & Human Retroviruses 14(18): 1653-1659, 1998

A phase II open-label, randomized study of the triple combination of Indinavir, zidovudine and didanosine versus Indinavir alone and zidovudine/didanosine in antiretroviral naive patients. INFECTIOUS DISEASES SOCIETY OF AMERICA [Author], NATIONAL INSTITUTES OF HEALTH [Author], CENTERS FOR DISEASE CONTROL AND PREVENTION [Author] 3rd Conference on retroviruses and opportunistic infections : 90, 1996

Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy. Journal of Virology 69(6): 3510-3516, 1995

Zidovudine therapy and HIV type 1 mutations in children with symptomatic HIV type 1 infection: effect of switching to didanosine or zidovudine plus didanosine therapy. Italian Multicenter Study Group on HIV Mutations in Children. Aids Research and Human Retroviruses 14(18): 1653-1659, 1998